Nitesh N Rao1,2,3, Michael B Stokes4, Adil Rajwani4,5, Shahid Ullah1,6, Kerry Williams4, David King2,7, Ewan Macaulay2,7, Christine H Russell2, Santosh Olakkengil2, Robert P Carroll1,2, Randall J Faull2, Karen S L Teo4, Stephen P McDonald1,2,6, Matthew I Worthley1,4,8, P Toby Coates1,2. 1. Adelaide Medical School, University of Adelaide, Australia (N.N.R., S.U., R.P.C., S.P.M., M.I.W., P.T.C.). 2. Central Northern Adelaide Renal and Transplantation Service (N.N.R., D.K., E.M., C.H.R., S.O., R.P.C., R.J.F., S.P.M., P.T.C.), Central Adelaide Local Health Network, Australia. 3. Lyell McEwin Hospital, Northern Adelaide Local Health Network, Australia (N.N.R.). 4. Department of Cardiology (M.B.S., A.R., K.W., K.S.L.T., M.I.W.), Central Adelaide Local Health Network, Australia. 5. Department of Cardiology, Royal Perth Hospital, Australia (A.R.). 6. Australia and New Zealand Dialysis and Transplant Registry 1 (S.U., S.P.M.), South Australian Health and Medical Research Institute, Adelaide. 7. Department of Vascular Surgery (D.K., E.M.), Central Adelaide Local Health Network, Australia. 8. Heart Health Theme (M.I.W.), South Australian Health and Medical Research Institute, Adelaide.
Abstract
BACKGROUND:Cardiovascular morbidity and mortality remain high in recipients of a kidney transplant. The persistence of a patent arteriovenous fistula (AVF) after transplantation may contribute to ongoing maladaptive cardiovascular remodeling. The ability to reverse this maladaptive remodeling by ligation of this AVF is unknown. We conducted the first randomized controlled trial to evaluate the effect of AVF ligation on cardiac structure and function in stable kidney transplant recipients. METHODS: In this randomized controlled trial, kidney transplant recipients (>12 months after transplantation with stable graft function) were randomized to AVF ligation or no intervention. All participants underwent cardiac magnetic resonance imaging at baseline and at 6 months. The primary outcome was the change in left ventricular (LV) mass. Secondary outcomes included changes in LV volumes, left and right atrial areas, LV ejection fraction, NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, cardiac output/index, brachial flows (ipsilateral to AVF), and pulmonary artery velocity. RESULTS: A total of 93 patients were screened, of whom 64 met the inclusion criteria and were randomized to the AVF ligation (n=33) or control (n=31) group. Fifty-four participants completed the study: 27 in the AVF ligation group and 27 in the control group. On the second cardiac magnetic resonance scan, a mean decrease of 22.1 g (95% CI, 15.0-29.1) was observed in LV mass in the AVF ligation group compared with a small increase of 1.2 g (95% CI, -4.8 to 7.2) in the control group ( P<0.001). Significant decreases in LV end-diastolic volumes, LV end-systolic volumes, cardiac output, cardiac index, atrial volumes, and NT-proBNP were also seen in the AVF closure group ( P<0.01). No significant changes were observed in LV ejection fraction ( P=0.93) and pulmonary artery velocity ( P=0.07). No significant complications were noted after AVF ligation. No changes in estimated glomerular filtration rate or systolic and diastolic blood pressures were observed between cardiac magnetic resonance scans. CONCLUSIONS:Elective ligation of patent AVF in adults with stable kidney transplant function resulted in clinically significant reduction of LV myocardial mass. CLINICAL TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry URL: https://www.anzctr.org.au . Unique Identifier: ACTRN12613001302741.
RCT Entities:
BACKGROUND: Cardiovascular morbidity and mortality remain high in recipients of a kidney transplant. The persistence of a patent arteriovenous fistula (AVF) after transplantation may contribute to ongoing maladaptive cardiovascular remodeling. The ability to reverse this maladaptive remodeling by ligation of this AVF is unknown. We conducted the first randomized controlled trial to evaluate the effect of AVF ligation on cardiac structure and function in stable kidney transplant recipients. METHODS: In this randomized controlled trial, kidney transplant recipients (>12 months after transplantation with stable graft function) were randomized to AVF ligation or no intervention. All participants underwent cardiac magnetic resonance imaging at baseline and at 6 months. The primary outcome was the change in left ventricular (LV) mass. Secondary outcomes included changes in LV volumes, left and right atrial areas, LV ejection fraction, NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, cardiac output/index, brachial flows (ipsilateral to AVF), and pulmonary artery velocity. RESULTS: A total of 93 patients were screened, of whom 64 met the inclusion criteria and were randomized to the AVF ligation (n=33) or control (n=31) group. Fifty-four participants completed the study: 27 in the AVF ligation group and 27 in the control group. On the second cardiac magnetic resonance scan, a mean decrease of 22.1 g (95% CI, 15.0-29.1) was observed in LV mass in the AVF ligation group compared with a small increase of 1.2 g (95% CI, -4.8 to 7.2) in the control group ( P<0.001). Significant decreases in LV end-diastolic volumes, LV end-systolic volumes, cardiac output, cardiac index, atrial volumes, and NT-proBNP were also seen in the AVF closure group ( P<0.01). No significant changes were observed in LV ejection fraction ( P=0.93) and pulmonary artery velocity ( P=0.07). No significant complications were noted after AVF ligation. No changes in estimated glomerular filtration rate or systolic and diastolic blood pressures were observed between cardiac magnetic resonance scans. CONCLUSIONS: Elective ligation of patent AVF in adults with stable kidney transplant function resulted in clinically significant reduction of LV myocardial mass. CLINICAL TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry URL: https://www.anzctr.org.au . Unique Identifier: ACTRN12613001302741.
Entities:
Keywords:
arteriovenous fistula; heart ventricles; kidney transplantation; magnetic resonance imaging
Authors: Tania Salehi; Nicholas J Montarello; Nishant Juneja; Michael B Stokes; Daniel J Scherer; Kerry F Williams; David King; Ewan Macaulay; Christine H Russell; Santosh A Olakkengil; Robert P Carroll; Randall J Faull; Karen S L Teo; Stephen P McDonald; Matthew I Worthley; Patrick T Coates; Nitesh N Rao Journal: Kidney360 Date: 2021-05-18
Authors: Colin R Lenihan; Sai Liu; Medha Airy; Carl Walther; Maria E Montez-Rath; Wolfgang C Winkelmayer Journal: Cardiorenal Med Date: 2021-09-02 Impact factor: 4.360
Authors: Patrick Hetz; Markus Pirklbauer; Silvana Müller; Lydia Posch; Maria Gummerer; Martin Tiefenthaler Journal: Am J Nephrol Date: 2020-07-13 Impact factor: 3.754
Authors: Jan Malik; Anna Valerianova; Vladimir Tuka; Pavel Trachta; Vladimira Bednarova; Zdenka Hruskova; Marcela Slavikova; Mitchell H Rosner; Vladimir Tesar Journal: ESC Heart Fail Date: 2021-03-23
Authors: Melissa C Caughey; Randal K Detwiler; Joseph A Sivak; Lisa J Rose-Jones; Abhijit V Kshirsagar; Alan L Hinderliter Journal: Transplantation Date: 2020-10 Impact factor: 5.385